The study concepts below have been endorsed by the Board of Directors following development and review by the Discipline-specific Advisories and Scientific Advisory Committee, and are currently seeking funds to commence the trial.
01.18 SUNBeAM
STING agonist + PD-1 inhibitor for patients diagnosed with metastatic uveal melanoma refractory to immunotherapy
